α-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons

Science Translational Medicine

Volumn 4, Issue 163, 2012, Pages

  Decressac, Mickael ^a   Kadkhodaei, Banafsheh ^b   Mattsson, Bengt ^a   Laguna, Ariadna ^b   Perlmann, Thomas ^b   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROTROPHIC FACTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; PARVOVIRUS VECTOR; PROTEIN BAD; PROTEIN KINASE B; PROTEIN RET; PROTEIN S6; TRANSCRIPTION FACTOR PITX3; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; NERVE CELL DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, KNOCKOUT; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

EID: 84870687953     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004676     Document Type: Article

References (66)

1. W. G. Meissner, M. Frasier, T. Gasser, C. G. Goetz, A. Lozano, P. Piccini, J. A. Obeso, O. Rascol, A. Schapira, V. Voon, D. M. Weiner, F. Tison, E. Bezard, Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 10, 377-393 ( 2011).
2. L. Aron, R. Klein, Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci. 34, 88-100 ( 2011).
3. A. Björklund, D. Kirik, C. Rosenblad, B. Georgievska, C. Lundberg, R. J. Mandel, Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886, 82-98 ( 2000).
4. D. Kirik, B. Georgievska, A. Björklund, Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7, 105-110 ( 2004).
5. J. H. Kordower, M. E. Emborg, J. Bloch, S. Y. Ma, Y. Chu, L. Leventhal, J. McBride, E. Y. Chen, S. Palfi, B. Z. Roitberg, W. D. Brown, J. E. Holden, R. Pysalski, M. D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Déglon, P. Aebischer, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 ( 2000).
6. S. Ramaswamy, K. E. Soderstrom, J. H. Kordower, Trophic factors therapy in Parkinson's disease. Prog. Brain Res. 175, 201-216 ( 2009).
7. R. T. Bartus, C. D. Herzog, Y. Chu, A. Wilson, L. Brown, J. Siffert, E. M. Johnson Jr., C. W. Olanow, E. J. Mufson, J. H. Kordower, Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26, 27-36 ( 2011).
8. S. S. Gill, N. K. Patel, G. R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D. J. Brooks, C. N. Svendsen, P. Heywood, Direct brain infusion of glial cell line - derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589-595 ( 2003).
9. A. E. Lang, S. Gill, N. K. Patel, A. Lozano, J. G. Nutt, R. Penn, D. J. Brooks, G. Hotton, E. Moro, P. Heywood, M. A. Brodsky, K. Burchiel, P. Kelly, A. Dalvi, B. Scott, M. Stacy, D. Turner, V. G. Wooten, W. J. Elias, E. R. Laws, V. Dhawan, A. J. Stoessl, J. Matcham, R. J. Coffey, M. Traub, Randomized controlled trial of intraputamenal glial cell line - derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459-466 ( 2006).
10. J. G. Nutt, K. J. Burchiel, C. L. Comella, J. Jankovic, A. E. Lang, E. R. Laws Jr., A. M. Lozano, R. D. Penn, R. K. Simpson Jr., M. Stacy, G. F. Wooten; ICV GDNF Study Group, Randomized, double-blind trial of glial cell line - derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73 ( 2003).
11. T. B. Sherer, B. K. Fiske, C. N. Svendsen, A. E. Lang, J. W. Langston, Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21, 136-141 ( 2006).
12. J. R. Cannon, J. T. Greenamyre, Neurotoxic in vivo models of Parkinson's disease recent advances. Prog. Brain Res. 184, 17-33 ( 2010).
13. M. J. Devine, K. Gwinn, A. Singleton, J. Hardy, Parkinson's disease and α-synuclein expression. Mov. Disord. 26, 2160-2168 ( 2011).
14. L. L. Venda, S. J. Cragg, V. L. Buchman, R. Wade-Martins, α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 33, 559-568 ( 2010).
15. C. Y. Chung, J. B. Koprich, H. Siddiqi, O. Isacson, Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV α-synucleinopathy. J. Neurosci. 29, 3365-3373 ( 2009).
16. M. Decressac, B. Mattsson, M. Lundblad, P. Weikop, A. Björklund, Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 45, 939-953 ( 2012).
17. M. Lundblad, M. Decressac, B. Mattsson, A. Björklund, Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 109, 3213-3219 ( 2012).
18. M. Decressac, A. Ulusoy, B. Mattsson, B. Georgievska, M. Romero-Ramos, D. Kirik, A. Björklund, GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain 134, 2302-2311 ( 2011).
19. C. Lo Bianco, N. Déglon, W. Pralong, P. Aebischer, Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 17, 283-289 ( 2004).
20. L. A. Volpicelli-Daley, K. C. Luk, T. P. Patel, S. A. Tanik, D. M. Riddle, A. Stieber, D. F. Meaney, J. Q. Trojanowski, V. M. Lee, Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71 ( 2011).
21. Z. Lei, Y. Jiang, T. Li, J. Zhu, S. Zeng, Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 70, 736-747 ( 2011).
22. C. Peng, L. Aron, R. Klein, M. Li, W. Wurst, N. Prakash, W. Le, Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J. Neurosci. 31, 12802-12815 ( 2011).
23. N. Volakakis, B. Kadkhodaei, E. Joodmardi, K. Wallis, L. Panman, J. Silvaggi, B. M. Spiegelman, T. Perlmann, NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc. Natl. Acad. Sci. U.S.A. 107, 12317-12322 ( 2010).
24. N. Bar, R. Dikstein, miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 5, e10859 ( 2010).
25. X. Ma, M. Kumar, S. N. Choudhury, L. E. Becker Buscaglia, J. R. Barker, K. Kanakamedala, M. F. Liu, Y. Li, Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 108, 10144-10149 ( 2011).
26. J. Kim, K. Inoue, J. Ishii, W. B. Vanti, S. V. Voronov, E. Murchison, G. Hannon, A. Abeliovich, A microRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224 ( 2007).
27. E. Doxakis, Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 285, 12726-12734 ( 2010).
28. E. Junn, K. W. Lee, B. S. Jeong, T. W. Chan, J. Y. Im, M. M. Mouradian, Repression of α-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U.S.A. 106, 13052-13057 ( 2009).
29. Y. Chu, W. Le, K. Kompoliti, J. Jankovic, E. J. Mufson, J. H. Kordower, Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 494, 495-514 ( 2006).
30. J. Goers, A. B. Manning-Bog, A. L. McCormack, I. S. Millett, S. Doniach, D. A. Di Monte, V. N. Uversky, A. L. Fink, Nuclear localization of α-synuclein and its interaction with histones. Biochemistry 42, 8465-8471 ( 2003).
31. E. Kontopoulos, J. D. Parvin, M. B. Feany, α-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012-3023 ( 2006).
32. H. Schell, T. Hasegawa, M. Neumann, P. J. Kahle, Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice. Neuroscience 160, 796-804 ( 2009).
33. M. Wakamatsu, A. Ishii, Y. Ukai, J. Sakagami, S. Iwata, M. Ono, K. Matsumoto, A. Nakamura, N. Tada, K. Kobayashi, T. Iwatsubo, M. Yoshimoto, Accumulation of phosphorylated α-synuclein in dopaminergic neurons of transgenic mice that express human α-synuclein. J. Neurosci. Res. 85, 1819-1825 ( 2007).
34. S. Yu, X. Li, G. Liu, J. Han, C. Zhang, Y. Li, S. Xu, C. Liu, Y. Gao, H. Yang, K. Uéda, P. Chan, Extensive nuclear localization of α-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 145, 539-555 ( 2007).
35. Y. Chu, A. L. Mickiewicz, J. H. Kordower, α-Synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol. Dis. 41, 71-82 ( 2011).
36. H. Jin, A. Kanthasamy, A. Ghosh, Y. Yang, V. Anantharam, A. G. Kanthasamy, α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J. Neurosci. 31, 2035-2051 ( 2011).
37. M. M. Maxwell, E. M. Tomkinson, J. Nobles, J. W. Wizeman, A. M. Amore, L. Quinti, V. Chopra, S. M. Hersch, A. G. Kazantsev, The sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet. 20, 3986-3996 ( 2011).
38. T. F. Outeiro, E. Kontopoulos, S. M. Altmann, I. Kufareva, K. E. Strathearn, A. M. Amore, C. B. Volk, M. M. Maxwell, J. C. Rochet, P. J. McLean, A. B. Young, R. Abagyan, M. B. Feany, B. T. Hyman, A. G. Kazantsev, Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519 ( 2007).
39. M. Decressac, B. Mattsson, A. Björklund, Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease. Exp. Neurol. 235, 306-315 ( 2012).
40. A. Quesada, H. E. Romeo, P. Micevych, Distribution and localization patterns of estrogen receptor-β and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat substantia nigra: Localization of ERβ and IGF-1R in the substantia nigra. J. Comp. Neurol. 503, 198-208 ( 2007).
41. A. Quesada, B. Y. Lee, P. E.Micevych, PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 68, 634-644 ( 2008).
42. L. Jiang, X. Liu, Z. Chen, Y. Jin, C. E. Heidbreder, A. Kolokythas, A. Wang, Y. Dai, X. Zhou, MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem. J. 432, 199-205 ( 2010).
43. B. Barneda-Zahonero, J. M. Servitja, N. Badiola, A. J. Miñano-Molina, R. Fadó, C. A. Saura, J. Rodríguez-Alvarez, Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival. J. Biol. Chem. 287, 11351-11362 ( 2012).
44. B. Kadkhodaei, T. Ito, E. Joodmardi, B. Mattsson, C. Rouillard, M. Carta, S. Muramatsu, C. Sumi-Ichinose, T. Nomura, D. Metzger, P. Chambon, E. Lindqvist, N. G. Larsson, L. Olson, A. Björklund, H. Ichinose, T. Perlmann, Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29, 15923-15932 ( 2009).
45. O. Saucedo-Cardenas, J. D. Quintana-Hau, W. D. Le, M. P. Smidt, J. J. Cox, F. De Mayo, J. P. Burbach, O. M. Conneely, Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. U.S.A. 95, 4013-4018 ( 1998).
46. R. H. Zetterström, L. Solomin, L. Jansson, B. J. Hoffer, L. Olson, T. Perlmann, Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248-250 ( 1997).
47. W. Le, O. M. Conneely, Y. He, J. Jankovic, S. H. Appel, Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73, 2218-2221 ( 1999).
48. M. R. Walton, I. Dragunow, Is CREB a key to neuronal survival? Trends Neurosci. 23, 48-53 ( 2000).
49. S. Azeredo da Silveira, B. L. Schneider, C. Cifuentes-Diaz, D. Sage, T. Abbas-Terki, T. Iwatsubo, M. Unser, P. Aebischer, Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 18, 872-887 ( 2009).
50. F. M. Jacobs, S. van Erp, A. J. van der Linden, L. von Oerthel, J. P. Burbach, M. P. Smidt, Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development 136, 531-540 ( 2009).
51. A. Tomac, J. Widenfalk, L. F. Lin, T. Kohno, T. Ebendal, B. J. Hoffer, L. Olson, Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. U.S.A. 92, 8274-8278 ( 1995).
52. S. Jain, J. P. Golden, D. Wozniak, E. Pehek, E. M. Johnson Jr., J. Milbrandt, RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. J. Neurosci. 26, 11230-11238 ( 2006).
53. E. R. Kramer, L. Aron, G. M. Ramakers, S. Seitz, X. Zhuang, K. Beyer, M. P. Smidt, R. Klein, Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 5, e39 ( 2007).
54. A. Pascual, M. Hidalgo-Figueroa, J. I. Piruat, C. O. Pintado, R. Gómez-Díaz, J. López-Barneo, Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11, 755-761 ( 2008).
55. Y. Chu, J. H. Kordower, Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol. Dis. 25, 134-149 ( 2007).
56. W. D. Le, P. Xu, J. Jankovic, H. Jiang, S. H. Appel, R. G. Smith, D. K. Vassilatis, Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33, 85-89 ( 2003).
57. P. M. Sleiman, D. G. Healy, M. M. Muqit, Y. X. Yang, M. Van Der Brug, J. L. Holton, T. Revesz, N. P. Quinn, K. Bhatia, J. K. Diss, A. J. Lees, M. R. Cookson, D. S. Latchman, N. W. Wood, Characterisation of a novel NR4A2 mutation in Parkinson's disease brain. Neurosci. Lett. 457, 75-79 ( 2009).
58. Z. Zhang, X. Li, W. Xie, H. Tuo, S. Hintermann, J. Jankovic, W. Le, Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol. Drug Targets 11, 768-773 ( 2012).
59. D. Engblom, A. Bilbao, C. Sanchis-Segura, L. Dahan, S. Perreau-Lenz, B. Balland, J. R. Parkitna, R. Luján, B. Halbout, M. Mameli, R. Parlato, R. Sprengel, C. Lüscher, G. Schütz, R. Spanagel, Glutamate receptors on dopamine neurons control the persistence of cocaine seeking. Neuron 59, 497-508 ( 2008).
60. E. M. Torres, E. L. Lane, A. Heuer, G. A. Smith, E. Murphy, S. B. Dunnett, Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates. J. Neurosci. Methods 200, 29-35 ( 2011).
61. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 6th ed. (Academic Press, San Diego, 1986).
62. U. Ungerstedt, G. W. Arbuthnott, Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493 ( 1970).
63. M. Åkerblom, R. Sachdeva, I. Barde, S. Verp, B. Gentner, D. Trono, J. Jakobsson, MicroRNA-124 is a subventricular zone neuronal fate determinant. J. Neurosci. 32, 8879-8889 ( 2012).
64. D. Grimm, Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 28, 146-157 ( 2002).
65. S. Zolotukhin, B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter, K. Chesnut, C. Summerford, R. J. Samulski, N. Muzyczka, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985 ( 1999).
66. P. J. Hallett, T. L. Collins, D. G. Standaert, A. W. Dunah, Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Curr. Protoc. Neurosci. Chapter 1, Unit 1.16 ( 2008).